A detailed history of Rhumbline Advisers transactions in Glaukos Corp stock. As of the latest transaction made, Rhumbline Advisers holds 136,012 shares of GKOS stock, worth $16.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
136,012
Previous 138,063 1.49%
Holding current value
$16.6 Million
Previous $11 Million 16.86%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$76.4 - $96.33 $156,696 - $197,572
-2,051 Reduced 1.49%
136,012 $12.8 Million
Q4 2023

Feb 08, 2024

SELL
$59.53 - $85.11 $194,305 - $277,799
-3,264 Reduced 2.31%
138,063 $11 Million
Q3 2023

Nov 09, 2023

BUY
$69.23 - $79.09 $62,791 - $71,734
907 Added 0.65%
141,327 $10.6 Million
Q2 2023

Aug 08, 2023

SELL
$45.44 - $71.21 $6,906 - $10,823
-152 Reduced 0.11%
140,420 $10 Million
Q1 2023

May 11, 2023

BUY
$43.88 - $52.48 $363,238 - $434,429
8,278 Added 6.26%
140,572 $7.04 Million
Q4 2022

Feb 14, 2023

BUY
$40.82 - $57.75 $116,786 - $165,222
2,861 Added 2.21%
132,294 $5.78 Million
Q3 2022

Nov 10, 2022

BUY
$46.84 - $58.49 $264,973 - $330,877
5,657 Added 4.57%
129,433 $6.89 Million
Q2 2022

Aug 11, 2022

BUY
$34.86 - $63.77 $205,360 - $375,669
5,891 Added 5.0%
123,776 $5.62 Million
Q1 2022

May 12, 2022

BUY
$44.33 - $57.82 $302,197 - $394,158
6,817 Added 6.14%
117,885 $6.82 Million
Q4 2021

Feb 10, 2022

BUY
$40.27 - $56.99 $22,510 - $31,857
559 Added 0.51%
111,068 $4.94 Million
Q3 2021

Nov 12, 2021

SELL
$47.43 - $84.23 $817,693 - $1.45 Million
-17,240 Reduced 13.5%
110,509 $5.32 Million
Q2 2021

Aug 05, 2021

BUY
$73.06 - $97.7 $36,530 - $48,850
500 Added 0.39%
127,749 $10.8 Million
Q1 2021

May 06, 2021

BUY
$70.43 - $97.42 $132,971 - $183,928
1,888 Added 1.51%
127,249 $10.7 Million
Q4 2020

Feb 10, 2021

BUY
$48.9 - $75.26 $234,817 - $361,398
4,802 Added 3.98%
125,361 $9.44 Million
Q3 2020

Nov 12, 2020

SELL
$37.23 - $50.97 $213,662 - $292,516
-5,739 Reduced 4.54%
120,559 $5.97 Million
Q2 2020

Aug 13, 2020

BUY
$28.78 - $46.83 $29,240 - $47,579
1,016 Added 0.81%
126,298 $4.85 Million
Q1 2020

May 06, 2020

BUY
$25.53 - $70.14 $1.79 Million - $4.92 Million
70,108 Added 127.07%
125,282 $3.87 Million
Q4 2019

Feb 05, 2020

BUY
$54.18 - $65.64 $361,163 - $437,556
6,666 Added 13.74%
55,174 $3.01 Million
Q3 2019

Oct 23, 2019

SELL
$58.58 - $83.91 $69,475 - $99,517
-1,186 Reduced 2.39%
48,508 $3.03 Million
Q2 2019

Aug 14, 2019

BUY
$63.59 - $78.71 $276,680 - $342,467
4,351 Added 9.6%
49,694 $3.75 Million
Q1 2019

May 01, 2019

BUY
$50.75 - $80.54 $27,506 - $43,652
542 Added 1.21%
45,343 $3.55 Million
Q4 2018

Jan 31, 2019

BUY
$52.18 - $67.93 $773,725 - $1.01 Million
14,828 Added 49.47%
44,801 $2.52 Million
Q3 2018

Nov 07, 2018

SELL
$38.13 - $68.37 $77,327 - $138,654
-2,028 Reduced 6.34%
29,973 $1.95 Million
Q2 2018

Aug 06, 2018

BUY
$27.62 - $44.51 $134,896 - $217,386
4,884 Added 18.01%
32,001 $1.3 Million
Q1 2018

May 02, 2018

SELL
$26.05 - $34.5 $15,109 - $20,010
-580 Reduced 2.09%
27,117 $836,000
Q4 2017

Feb 09, 2018

SELL
$24.5 - $36.01 $125,366 - $184,263
-5,117 Reduced 15.59%
27,697 $710,000
Q3 2017

Nov 06, 2017

BUY
$31.26 - $42.03 $1.03 Million - $1.38 Million
32,814
32,814 $1.08 Million

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $5.8B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.